Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
The Japanese government has awarded Takeda Pharmaceutical $312 million to help it invest in pandemic H5N1 flu vaccine development and manufacturing. The company is in the process of implementing in Japan a flu vaccine technology, based on Vero cells, that it licensed from Baxter International. Takeda will proceed with the construction of a commercial facility at its Hikari site, with the aim of obtaining regulatory approval for its vaccines during the 2013 fiscal year. Last year, Japan provided $47 million for the company to test Baxter’s cell-culture and purification techniques at Hikari.
This article has been sent to the following recipient: